Evidence map›Paper›PMID 39188994›Full record

ArticleAdvances in radiation oncology2024

Comparative Analysis of Recurrent Glioblastoma Target Contours via

Gianluca Ferini, Gianluca Scalia, Mandara Harikar, Valentina Zagardo, Luigi Castorina, Alessio Comis, Andrea Boncoraglio, Bipin Chaurasia, Paolo Palmisciano, Giuseppe E Umana

Abstract read
In one paragraph

Article in Advances in radiation oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Gianluca FeriniDepartment of Radiation Oncology, REM Radioterapia srl, Viagrande, Italy.
Gianluca ScaliaDepartment of Head and Neck Surgery, Neurosurgery Unit, Garibaldi Hospital, Catania, Italy.
Mandara HarikarClinical Trials Programme, Usher Institute of Molecular, Genetic and Population Health Sciences, University of Edinburgh, Edinburgh, United Kingdom.
Valentina ZagardoDepartment of Radiation Oncology, REM Radioterapia srl, Viagrande, Italy.
Luigi CastorinaDepartment of Nuclear Medicine, REM Radioterapia srl, Viagrande, Italy.
Alessio ComisDepartment of Nuclear Medicine, REM Radioterapia srl, Viagrande, Italy.
Andrea BoncoraglioRadiology Unit, Giovanni Paolo II Hospital, Ragusa, Italy.
Bipin ChaurasiaDepartment of Neurosurgery, Neurosurgery Clinic, Birgunj, Nepal.
Paolo PalmiscianoDepartment of Neurosurgery, UC Davis, Davis, California.
Giuseppe E UmanaDepartment of Medicine and Surgery, University Kore of Enna, 94100 Enna, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Glioblastoma (GBM) recurrence poses challenges in radiation therapy treatment planning because reirradiation has limited leeway needed for precise target delineation. Although effective radiotracers are emerging for treatment planning, comparisons of Methods and Materials: A 37-year-old female patient with recurrent Isocitrate dehydrogenase (IDH)1/2 wild-type GBM underwent MRI, MET-PET, and PSMA-PET scans. Target delineations were performed, and volumes were compared using the Dice similarity coefficient, conformity index, and overlap volume, considering different planning target volume margins. Results: We found that MET-PET and MRI volumes showed superior agreement compared with PSMA-PET across all similarity parameters, indicating a more marked discrepancy between PSMA-PET and other modalities. Increasing planning target volume margins demonstrated progressive convergence in intervolume discrepancies. Notably, PSMA-PET delineated larger volumes extending beyond MRI-based volumes. Conclusions: MRI alone may not suffice for target delineation in recurrent GBMs. PET imaging modalities offer complementary insights. Combined PET-MRI guidance could improve tumor boundary detection in target delineation for reirradiation. Prospective trials are necessary to ascertain its impact on patient outcomes.

Identifiers

PMID39188994
PMCPMC11345295

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.